An international research team is perfecting a method to predict the potential clinical implications of new drugs before clinical trials even start.
An international research team has developed a new strategy that can predict the potential clinical implications of new therapeutic compounds based on simple cellular responses. This discovery was partly led by scientists affiliated with Université de Montréal (UdeM), and represents a major step forward in developing more effective drugs with fewer side effects, much faster than before. The researchers conducted their work at Centre de Recherche de l’Hôpital Ste-Justine and published their findings in the prestigious journal Nature Communications.
Developing new drugs is a long, complex and costly process. It starts with identifying the molecule or “ligand” (such as a drug, hormone or neurotransmitter) that can activate or block the target or “receptor” involved in a disease. Compound identification and validation is one of the most important steps in ensuring that a new drug provides an effective clinical response with the fewest possible side effects.
“Most new drugs tested on human subjects fail in clinical trials because the therapeutic response is insufficient. Developing a strategy that infers potential clinical responses early in the drug discovery process would significantly improve drug candidate selection,” said Besma Benredjem, the study’s co-lead author and a doctoral student in pharmacology at UdeM.
Finding the needle in a haystack
“Our main goal was finding a way to categorize a large number of drug candidates based on similarities in their effectiveness in triggering a multiplicity of cellular responses that help identify the therapeutic action of new compounds,” said Professor Graciela Piñeyro, co-senior author of the study and a researcher at CHU Sainte-Justine. To accomplish this, she worked with Dr. Olivier Lichtarge of Baylor College of Medicine, who uses advanced bioinformatic analysis to compare and group ligands according to fairly comprehensive signalling profiles.
Drugs produce desired or undesired clinical actions by changing basic signals within cells. By grouping drugs with known clinical actions and new ligands, we can infer the clinical actions of new compounds by comparing the similarities and differences in their signals with known drugs to promote desired clinical responses and avoid side effects.
This method of analysis was developed by using opioid analgesics as prototypes. This made it possible for the team to associate simple cellular signals produced by opioids such as oxycodone, morphine and fentanyl with the frequency with which respiratory depression and other undesirable side effects of these drugs were reported to the Food and Drug Administration’s pharmacovigilance program. At the height of the opioid epidemic, when the risk of death by respiratory depression is at its highest, the team believes this new analytical strategy could lead to the development of safer opioids.
“Thanks to our findings, we can now classify a large number of compounds while taking a multitude of cellular signals into account. The wealth of comparisons this provides increases this classification’s predictive value for clinical responses,” said Professor Michel Bouvier, the study’s co-senior author and a principal investigator of molecular pharmacology and Chief Executive Officer of UdeM’s Institute for Research in Immunology and Cancer. “We think we can help patients by speeding up the drug discovery process so clinical trials can start earlier.”
“Our next goal is to use a similar approach to test cannabis products that may produce harmful neuropsychiatric actions among young people, and identify which cannabis extracts are most effective at treating chronic pain,” added Besma Benredjem.
The Latest on: Drug development
via Google News
The Latest on: Drug development
- Global Antibiotic Resistance Markets, 2020-2024: New Technologies and New Drugs are Under Development to Capture this Growing Marketon October 7, 2020 at 1:32 pm
New Technologies and New Drugs are Under Development to Capture this Growing Market DUBLIN, Oct. 7, 2020 /PRNewswire/ -- The "Antibiotic Resistance Markets - Therapeutics By Pathogen and Therapy Type ...
- Promising Data Prompts Eli Lilly To Seek FDA Authorization for Antibody Drugon October 7, 2020 at 1:00 pm
The company also announced positive interim data from a clinical trial of a drug with a combination of two neutralizing antibodies.
- Ironic Twist: Last Spring Trump Halted Research Key To COVID-19 Drug He's Now Takenon October 7, 2020 at 11:51 am
The drug, Remdesivir, emerged in part because researchers had previously tested it in China through a project whose grant was abruptly ended by the National Institutes of Health.
- Eli Lilly Seeks Emergency Authorization For Covid-19 Drug, May Produce 100,000 Doses By Month-Endon October 7, 2020 at 11:42 am
Eli Lilly has requested emergency authorization from the Food and Drug Administration (FDA) for its monoclonal antibody treatment, which helps reduce the rate of hospitalization for Covid-19 patients ...
- New CU Anschutz technology could speed up drug development in the Mountain Weston October 7, 2020 at 11:09 am
University of Colorado Anschutz Medical Campus is obtaining new technology that is going to open up new opportunities for drug development. The new technology system consists of robotic screening and ...
- AI tool could predict how drugs will react in the bodyon October 7, 2020 at 10:55 am
Metabolic Translator, a new deep-learning tool, may offer a way to see how drugs in development will work in the body, not just the lab.
- Development of precision drug delivery tool to treat traumatic brain injuryon October 7, 2020 at 5:42 am
An interdisciplinary team of researchers at the University of Southern California has developed a precision drug delivery tool to selectively treat areas of the brain damaged during a traumatic brain ...
- Healthcare Leaders Pioneer A New Collaboration Model To Transform The Future Of Drug Developmenton October 6, 2020 at 5:58 am
The reinvention of drug development through partnership was the the theme of this breakthrough discussion of leaders. Through collaboration and use of AI in drug development new barriers can be broken ...
- New deep learning-based technique could boost drug developmenton October 5, 2020 at 3:08 pm
When you take a medication, you want to know precisely what it does. Pharmaceutical companies go through extensive testing to ensure that you do.
- Nvidia Partners With GlaxoSmithKline to Use AI for Drug Developmenton October 5, 2020 at 12:22 pm
Nvidia also is building what it says is the U.K.'s most powerful supercomputer to help research pressing medical challenges.
via Bing News